

=> d his ful

(FILE 'HOME' ENTERED AT 11:41:08 ON 15 MAR 2005)

FILE 'HCAPLUS' ENTERED AT 11:44:42 ON 15 MAR 2005

E PRENDERGAST PATRICK/AU

L1 13 SEA ABB=ON ("PRENDERGAST P"/AU OR "PRENDERGAST P J"/AU OR
"PRENDERGAST PATRICK"/AU OR "PRENDERGAST PATRICK J"/AU)
L2 0 SEA ABB=ON L1 AND CHEMOTHERAP?
L3 0 SEA ABB=ON L1 AND ?COMB? (W) ?THERAPY?
D TI L1 1-13
L4 0 SEA ABB=ON L1 AND ?NEOPLAS?
L5 0 SEA ABB=ON L1 AND ?CIRCILIOI?

FILE 'REGISTRY' ENTERED AT 11:47:47 ON 15 MAR 2005

E CIRCILIOI/CN

L6 0 SEA ABB=ON WPID

FILE 'WPIDS' ENTERED AT 11:50:33 ON 15 MAR 2005

E PRENDERGAST PATRICK/AU

L7 30 SEA ABB=ON ("PRENDERGAST P"/AU OR "PRENDERGAST P T"/AU)
L8 6 SEA ABB=ON L7 AND ?CHEMOTHERAP?

FILE 'HCAPLUS' ENTERED AT 12:00:19 ON 15 MAR 2005

L9 1 SEA ABB=ON ?CIRCILIOI?
SELECT RN L9 1-1

FILE 'REGISTRY' ENTERED AT 12:00:51 ON 15 MAR 2005

L10 9 SEA ABB=ON (105226-41-3/BI OR 151345-08-3/BI OR 155862-53-6/BI
OR 34334-69-5/BI OR 480-41-1/BI OR 520-12-7/BI OR 520-36-5/BI
OR 638-95-9/BI OR 77-52-1/BI)

FILE 'HCAPLUS' ENTERED AT 12:01:07 ON 15 MAR 2005

L11 1 SEA ABB=ON L9 AND L10

FILE 'REGISTRY' ENTERED AT 12:04:24 ON 15 MAR 2005

E GEMCITABINE/CN

L12 1 SEA ABB=ON GEMCITABINE/CN
L13 1 SEA ABB=ON 34334-69-5/RN
E 2,3,4-TRIMETHOXY ACETOPHENONE/CN
E ACETOPHENONE 2,3,4-TRIMETHOXY/CN
L14 1 SEA ABB=ON "ACETOPHENONE 4-METHYLPHENYLHYDRAZONE"/CN
E ACETOPHENONE/CN
L15 1 SEA ABB=ON ACETOPHENONE/CN
E FLAVONE/CN
L16 1 SEA ABB=ON FLAVONE/CN

FILE 'HCAPLUS' ENTERED AT 12:20:05 ON 15 MAR 2005

L17 1944 SEA ABB=ON L12
L18 109134 SEA ABB=ON ?ACETOPHENON? OR ?FLAVON? OR ?METHOXYDIBENZOYL? OR
?CIRCILIOI?
L19 5450 SEA ABB=ON L18 AND (?CHEMOTHERAP? OR ?NEOPLAS? OR ?ANTI? (W) (?C
ANCER? OR ?PARASIT? OR ?VIRAL? OR ?BACTER?) OR ?ANTIVIRAL? OR
?ANTIBACT? OR ?ANTIPARASIT? OR ?ANTICANCER? OR ?ANTIBIOTIC?)
L20 6836 SEA ABB=ON L19 AND ?RADIATION? OR ?PANCREATIC? (W) (?CANCER? OR
?NEOPLASM? OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR?)
L21 126 SEA ABB=ON L19 AND (?RADIATION? OR ?PANCREATIC? (W) (?CANCER?
OR ?NEOPLASM? OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR?))
L22 0 SEA ABB=ON L21 AND (?PHARM? OR ?DRUG?) (W) ?FORMUL?

L23 62 SEA ABB=ON L21 AND (?PHARM? OR ?DRUG?)
L24 2 SEA ABB=ON L23 AND ?MIMIC?
L25 3 SEA ABB=ON L9 OR L24
DELETE SELECT
SELECT RN L25 1-3

FILE 'REGISTRY' ENTERED AT 12:34:06 ON 15 MAR 2005
L26 87 SEA ABB=ON (104227-87-4/BI OR 106941-25-7/BI OR 113852-37-2/BI etc.

FILE 'HCAPLUS' ENTERED AT 12:34:20 ON 15 MAR 2005
L27 3 SEA ABB=ON L25 AND L26

FILE 'REGISTRY' ENTERED AT 13:35:09 ON 15 MAR 2005
L28 STR
L29 4 SEA SSS SAM L28
L30 78 SEA SSS FUL L28
L31 STR L28
L32 STR
L33 1 SEA SSS SAM L32
L34 16 SEA SSS FUL L32
L35 STR L32
L36 STR L35
L37 0 SEA SSS SAM L36
L38 0 SEA SSS FUL L36
L39 STR L36
L40 0 SEA ABB=ON 153-866-57-0/RN
L41 0 SEA ABB=ON 153-866-57/RN
L42 94 SEA ABB=ON L30 OR L34

FILE 'HCAPLUS' ENTERED AT 13:44:45 ON 15 MAR 2005
L43 330 SEA ABB=ON L42
L44 25 SEA ABB=ON L43 AND (?CHEMOTHERAP? OR ?NEOPLAS? OR ?ANTICANCER?
OR ?ANTIVIRAL? OR ?ANTIBACT? OR ?ANTIPARASIT? OR ?ANTIBIOTIC?)
L45 0 SEA ABB=ON L43 AND (?ANTIMETABOLIT? OR ?NUCLEOTIDE?(W)?ANALOG?
OR ?NUCLEOSIDE?(W)?ANALOG?)
L46 3 SEA ABB=ON L43 AND (?METABOLIT? OR ?NUCLEOTIDE?(W)?ANALOG? OR
?NUCLEOSIDE?(W)?ANALOG?)
L47 0 SEA ABB=ON L43 AND ?PANCREA?

FILE 'REGISTRY' ENTERED AT 13:48:02 ON 15 MAR 2005
L48 1 SEA ABB=ON 34334-69-5/RN
L49 95 SEA ABB=ON L42 OR L48

FILE 'HCAPLUS' ENTERED AT 13:49:18 ON 15 MAR 2005
L50 483 SEA ABB=ON (L49 OR ?CIRCILIOI?)
L51 33 SEA ABB=ON L50 AND (?CHEMOTHERAP? OR ?NEOPLAS? OR ?ANTICANCER?
OR ?ANTIVIRAL? OR ?ANTIBACT? OR ?ANTIPARASIT? OR ?ANTIBIOTIC?)
L52 0 SEA ABB=ON L50 AND (?ANTIMETABOLIT? OR ?NUCLEOTIDE?(W)?ANALOG?
OR ?NUCLEOSIDE?(W)?ANALOG?)
L53 1 SEA ABB=ON L50 AND ?PANCREA?
L54 33 SEA ABB=ON L51 OR L53
L55 1 SEA ABB=ON L54 AND (L12 OR ?GEMCITABINE?)
L56 33 SEA ABB=ON L54 OR L55
L57 2 SEA ABB=ON L56 AND ?RADIAT?
L58 33 SEA ABB=ON L56 OR L57
L59 13 SEA ABB=ON L58 AND (?PHARM? OR ?DRUG?)
L60 33 SEA ABB=ON L58 OR L59
L61 24 SEA ABB=ON L60 AND (PRD<20010306 OR PD<20010306)

*24 citz from
CA Plus*

=> d ibib abs ind l8 4

L8 ANSWER 4 OF 6 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2003-046729 [04] WPIDS
 DOC. NO. CPI: C2003-011832
 TITLE: Composition, useful in the treatment of, e.g. neoplasia, viral or parasitic infection, comprises at least one compound selected from circiliol, acetophenone and flavone derivatives, and an additive, diluent, carrier or excipient.
 DERWENT CLASS: A96 B05
 INVENTOR(S): PRENDERGAST, P T
 PATENT ASSIGNEE(S): (PREN-I) PRENDERGAST P T
 COUNTRY COUNT: 100
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002069949	A2	20020912	(200304)*	EN	66
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
US 2002169140	A1	20021114	(200304)		
AU 2002238799	A1	20020919	(200433)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002069949	A2	WO 2002-IB632	20020305
US 2002169140	A1	US 2002-91855	20020306
AU 2002238799	A1	AU 2002-238799	20020305

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002238799	A1 Based on	WO 2002069949

PRIORITY APPLN. INFO: IE 2001-209 20010306

AN 2003-046729 [04] WPIDS

AB WO 200269949 A UPAB: 20030117

NOVELTY - A composition (I) comprises:

(A) at least one micronized compound (A) selected from circiliol, acetophenone and flavone derivatives; and

(B) an additive, diluent, carrier, excipient or their salts.

DETAILED DESCRIPTION - A composition (I) comprises:

(A) at least one micronized compound (A) selected from circiliol, 6-hydroxy-2,3,4-trimethoxy acetophenone; 2-(3,4-dibenzyloxybenzoyloxy)-4,5,6-trimethoxy acetophenone, 3'4'-dibenzyloxy-2-hydroxy-4,5,6-trimethoxydibenzoyl methane, 6,7 -dibenzyloxy-5,6,7-trimethoxy flavone, 3,4-dihydroxy-5,6,7-trimethoxy flavone, 3,4-diacetoxy-5,6,7-trimethoxy flavone, their derivatives, metabolites, analogs and/or mimic molecules; and

(B) an additive, diluent, carrier, excipient or their salts.

INDEPENDENT CLAIMS are also included for:

(1) Pharmaceutical formulation (II) comprising (I), at least one chemotherapeutic agent and a carrier for the agent; and

(2) Methods of treating a patient suffering from neoplasia, viral infection or parasitic comprising the administration of (I).

ACTIVITY - Cytostatic; Anti-HIV; Protozoacide; Anti-tumor; Virucide; Immunomodulator; Antibacterial.

No biological data available.

MECHANISM OF ACTION - Neoplastic cell proliferation inhibitor; Tumor growth inhibitor.

The in vitro growth of circiliol (A) was tested in large cell lung cancer line LXFL 529L and lung adenocarcinoma cell line LXFA 526L in a modified propidium iodide assay as described in Dengler et al. (1995). (A) was dissolved in dimethylsulfoxide at a stock concentration of 100 mg/ml and stored at 4 deg. C. It was observed that both cell lines grew very well with initial cell number increasing 4-fold.

(A) at concentration of 30 mu g/ml and 300 mu g/ml resulted in tumor growth inhibition of 39 - 56%.

USE - (I) is used in the manufacture of a medicament for treatment of a mammal (e.g. neonate) suffering from:

(a) a neoplasia, e.g. precancerous lesion including syndromes represented by abnormal neoplastic and/or dysplastic, changes of tissue comprising precancerous growths in colonic, breast, renal, central nervous, gastric, or lung tissues, or conditions such as dysplastic nevus syndrome, precursor to malignant melanoma of the skin, dysplastic nevus syndromes, polyposis syndromes, colonic polyps, precancerous lesions of the cervix (i.e. cervical dysplasia), prostatic dysplasia, bronchial dysplasia, breast, bladder and/or skin and related conditions (e.g. actinic keratosis), prostate cancer, colon cancer, small cell lung cancer, large cell lung cancer, lung adenocarcinoma, epidermoid lung cancer, melanoma (including amelanotic subtypes), renal cell carcinoma, gastric carcinoma, cancers of the central nervous system including brain tumors, neuroblastomas, gastric carcinoma, breast cancer, ovarian cancer, testicular cancer, lymphoma and leukemia, oesophageal cancer, stomach cancer, liver cancers, prostate cancer, cervical cancer, adrenal cancer, oral or mucosal cancer, bladder cancer, pancreatic cancer, lymphoma, Hodgkin's disease, sarcomas, haematopoietic cell cancers such as B cell leukaemia/lymphomas, myelomas, T-cell leukemias/lymphomas, small cell leukemias/lymphomas, null cell, sezary, monocytic, myelomonocytic and hairy cell leukemias, a tumour including an epidermoid or myeloid tumour, acute or chronic, nonsmall cell, squamous or solid;

(b) a viral infection condition by DNA viruses and RNA viruses (e.g. HIV, SHIV, SIV, FIV, HSV, CMV, HAV, HBV, HCV, HDV, HEV, EBV, BVDV, HSV-1, HSV-2, HSV-6, HHV-6, HHV-8, retrovirus infection, togavirus infection, flavivirus infection, rubivirus infection, pestivirus infection, lipid envelope virus infection, filovirus, picomavirus infection, rhinovirus infection, coronavirus infection, respiratory syncytial virus infection, poliovirus infection, parainfluenza virus infection, influenza virus infection, hantavirus, adeno-associated virus, measles virus, poxvirus, filovirus, human papilloma virus and animal papilloma virus infection), at least one complication or co-infection associated with AIDS, AIDS related syndromes, including cachexia and/or wasting syndrome; or

(c) a parasite infection condition by Trypanosoma (e.g. Trypanosoma cruzi, Trypanosoma brucei, Trypanosoma gambiense or Trypanosoma rhodesiense), Plasmodium (e.g. Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Plasmodium berghei), Entamoeba (e.g. Entamoeba histolytica), Balantidium (e.g. Balantidium coli), Leishmania (e.g. Leishmania braziliensis, Leishmania mexicana, Leishmania donovani or Leishmania tropica), Penumocystis (e.g. Penumocystis carinii), Trichomoniasis (e.g. Trichomoniasis vaginalis), or Toxoplasma (e.g. Toxoplasma gondii), to treat malaria, sleeping sickness, African

trypanosomiasis, Chagas disease, American trypanosomiasis, cryptosporidiosis, amebiasis, balantidiasis, giardiasis, leishmaniasis, pneumocystosis, trichomoniasis, toxoplasmosis; a bacterial infection (intracellular or extracellular) condition such as mycoplasma infection, Listeria infection, Mycobacterium infection, Streptococcus infection, Staphylococcus infection, Vibrio infection, Salmonella infection, shigella infection, enterotoxigenic, enteropathogenic, enteroinvasive or enterohemorrhagic E. coli infection, Yersinia infection, Campylobacter infection, Pseudomonas infection, Borrelia infection, Legionella infection, Haemophilus infection, pulmonary Aspergillosis, mucosal or oropharyngeal candidiasis or juvenile paracoccidiomycosis; or

For treatment of a subject for suppression of immune response rejection in tissue transplantation (all claimed).

ADVANTAGE - (I) endows a chemotherapeutic agent with substantially enhanced therapeutic efficacy and reduced toxicity.

Dwg.0/2

AN 2003-046729 [04] WPIDS
 DC A96 B05
 IC ICM A61K031-00
 ICS A61K009-127; A61K009-16; A61K009-32; A61K009-36; A61K031-12;
 A61K031-235; A61K031-353; A61K039-395; A61K039-42; A61K039-44;
 A61P031-00; A61P031-04; A61P031-12; A61P031-18; A61P033-00;
 A61P035-00; A61P037-06
 ICA A61K031-137; A61K031-155; A61K031-185; A61K031-191; A61K031-341;
 A61K031-352; A61K031-365; A61K031-407; A61K031-4164; A61K031-4375;
 A61K031-4706; A61K031-4709; A61K031-473; A61K031-505; A61K031-513;
 A61K031-52; A61K031-522; A61K031-541; A61K031-555; A61K031-65;
 A61K031-7048; A61K031-7056; A61K031-7064; A61K031-7068; A61K031-7072;
 A61K031-7076
 MC CPI: A12-V01; B02-A; B02-T; B04-A02; B04-B03A; B04-B03B; B05-A02;
 B05-B01C; B06-H; B07-H; B10-A09B; B10-A10; B10-A17; B10-B02J;
 B10-B03B; B10-E02; B10-G02; B12-M11F; B14-A01; B14-A02; B14-A02B1;
 B14-A03; B14-B02; B14-G02C; B14-G03; B14-H01; B14-H01A; B14-H01B;
 B14-J01A2; B14-J01A4
 DRN 0020-U; 0036-U; 0037-U; 0078-U; 0084-U; 0153-U; 0165-U; 0177-U; 0210-U;
 0285-S; 0285-U; 0287-U; 0295-S; 0295-U; 0303-U; 0318-S; 0318-U; 0472-U;
 0479-S; 0479-U; 1096-U; 1243-U; 1257-U; 1259-U; 1382-U
 PLE UPA 20030117
 [1.1] 018; R00479 G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26 D51 D53
 D58 D63 D85 F41 F89; H0000; P0088; P0113
 [1.2] 018; R00009 G2108 D01 D11 D10 D50 D60 D83 F27 F26 F36 F35;
 R00448 G2108 D01 D11 D10 D50 D60 D82 F27 F26 F36 F35; H0022
 H0011; P1978-R P0839 D01 D50 D63 F41
 [1.3] 018; R16917 G3645 G3634 G3623 D01 D03 D10 D11 D18 D19 D22 D23
 D42 D50 D63 E19 F24 F34 F41 P0599 H0293
 [1.4] 018; G3690 G3634 G3623 P0599 D01 D03 D11 D23 D42 D63 D76 F24 F34
 H0293 E19 E00 D19 D18 D50 F26-R F41-R
 [1.5] 018; R00657 G0395 G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26
 D51 D53 D58 D63 D88 F41 F89; H0000; P0088
 [1.6] 018; R01606 G0384 G0339 G0260 G0022 D01 D11 D10 D12 D26 D51 D53
 D58 D63 D88 F08 F07 F41 F89; H0000; P0088
 [1.7] 018; ND01; Q9999 Q8037 Q7987
 CMC UPB 20030117
 M1 *83* M423 M431 M782 M905
 DCN: R16918-K; R16918-Q; R16918-M; RA0NLR-K; RA0NLR-Q; RA0NLR-M
 M1 *84* H7 H721 J0 J011 J2 J271 M210 M213 M214 M231 M232 M262 M272
 M281 M320 M423 M431 M782 M904 M905
 DCN: RA0OES-K; RA0OES-Q; RA0OES-M
 M1 *85* H4 H401 H481 H8 J0 J011 J1 J171 M280 M311 M312 M321 M331
 M340 M342 M349 M381 M391 M416 M423 M431 M620 M782 M904 M905

DCN: RA0B83-K; RA0B83-M

M1 *86* G011 G100 J0 J011 J012 J1 J131 J2 J221 M1 M123 M136 M210
M211 M262 M280 M281 M320 M423 M431 M510 M520 M530 M531 M540 M782
M904 M905

DCN: R16917-K; R16917-M; RA0B9L-K; RA0B9L-M

M1 *89* M423 M431 M782 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452
P631 P632 P633

DCN: RA1FGW-K; RA1FGW-T; RA1FGW-M

M1 *90* D015 D019 D023 D025 E470 E499 E510 H1 H100 H141 J0 J012 J3
J322 J5 J523 L9 L941 L942 L999 M1 M125 M129 M136 M139 M210
M211 M240 M283 M320 M423 M431 M513 M520 M530 M540 M782 M904 M905
P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
RIN: 11946

DCN: RA169M-K; RA169M-T; RA169M-M

M2 *01* D013 D024 D120 G015 G100 H5 H543 H8 J0 J012 J2 J242 J5
J521 M1 M113 M210 M211 M262 M272 M282 M283 M320 M412 M431 M511
M520 M531 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434
P446 P452 P631 P632 P633

DCN: RA8RNF-K; RA8RNF-T; RA8RNF-M

M2 *02* D013 D024 D120 G015 G100 H4 H402 H442 H5 H543 H8 J5 J521
M1 M113 M210 M211 M272 M283 M320 M412 M431 M511 M520 M531 M540
M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631
P632 P633

DCN: RA8RNC-K; RA8RNC-T; RA8RNC-M

M2 *03* D013 D024 D026 D029 D120 G010 G019 G100 H5 H561 H8 J5 J521
K0 L6 L660 L699 M1 M113 M210 M211 M272 M283 M311 M322 M342
M373 M392 M412 M431 M511 M520 M533 M540 M782 M904 M905 P210 P220
P310 P330 P431 P433 P434 P446 P452 P631 P632 P633

DCN: RA8RLU-K; RA8RLU-T; RA8RLU-M

M2 *04* G010 G019 G037 G038 G113 G561 H5 H563 H8 J0 J011 J2 J251
J5 J581 K0 L6 L660 M210 M211 M272 M283 M311 M323 M342 M349
M373 M381 M391 M392 M414 M431 M510 M520 M533 M541 M782 M904 M905
P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633

DCN: RA8RLT-K; RA8RLT-T; RA8RLT-M

M2 *05* G010 G015 G018 G019 G100 H4 H401 H441 H5 H543 H8 J5 J582
M1 M121 M135 M210 M211 M272 M283 M311 M323 M342 M373 M382 M391
M392 M414 M431 M510 M520 M533 M540 M782 M904 M905 P210 P220 P310
P330 P431 P433 P434 P446 P452 P631 P632 P633

DCN: RA8R4U-K; RA8R4U-T; RA8R4U-M

M2 *06* G018 G100 H4 H401 H441 H5 H543 H8 J5 J581 M210 M211 M262
M272 M281 M283 M320 M414 M431 M510 M520 M531 M540 M782 M904 M905
P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633

DCN: RA8R4T-K; RA8R4T-T; RA8R4T-M

M2 *07* F012 F014 F542 H1 H100 H121 J5 J521 L9 L910 M280 M320 M413
M431 M510 M521 M530 M540 M782 M904 M905 M910 P210 P220 P310 P330
P431 P433 P434 P446 P452 P631 P632 P633

DCN: R00303-K; R00303-T; R00303-M

M2 *08* F011 F012 F013 F014 F015 F019 F113 F580 H1 H100 H121 H2 H211
H4 H403 H422 H481 H8 J5 J521 K0 L8 L812 L821 L834 L9
L910 L999 M280 M311 M321 M342 M373 M391 M413 M431 M510 M522 M530
M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452
P631 P632 P633
RIN: 00212

DCN: R08216-K; R08216-T; R08216-M

M2 *09* F011 F012 F521 G010 G100 H1 H181 H2 H201 H3 H321 J0 J011
J3 J371 L922 M280 M311 M322 M342 M349 M373 M381 M391 M413 M431
M510 M521 M531 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433
P434 P446 P452 P631 P632 P633

DCN: RA0DQR-K; RA0DQR-T; RA0DQR-M

M2 *10* B633 B712 B722 B741 B823 B831 B840 F012 F014 F016 F019 F240 F580

G013 G100 H1 H101 H102 H123 H4 H401 H481 H8 L910 L999 M1
 M123 M143 M280 M311 M321 M342 M373 M391 M411 M431 M510 M522 M531
 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452
 P631 P632 P633
 RIN: 00064 00212
 DCN: RA095K-K; RA095K-T; RA095K-M
 M2 *11* G012 G015 G019 G022 G029 G113 G221 G299 J0 J014 J3 J332 K0
 K4 K431 K499 L4 L432 M1 M121 M122 M129 M136 M137 M139 M210
 M211 M240 M282 M320 M414 M431 M510 M520 M533 M540 M782 M904 M905
 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R04427-K; R04427-T; R04427-M
 M2 *12* C316 F011 F012 F013 F014 F015 F018 F111 F740 H2 H211 H3 H321
 K0 K4 K441 K6 K630 M210 M211 M240 M281 M320 M413 M431 M510
 M522 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434
 P446 P452 P631 P632 P633
 RIN: 00245
 DCN: R18588-K; R18588-T; R18588-M
 M2 *13* C316 F012 F013 F014 F015 F541 F620 G013 G017 G100 H1 H100 H101
 H122 H141 H543 K353 L910 L943 M1 M123 M132 M147 M210 M211 M240
 M272 M281 M283 M311 M320 M321 M342 M413 M431 M510 M521 M531 M540
 M650 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452
 P631 P632 P633
 DCN: RA00LG-K; RA00LG-T; RA00LG-M
 M2 *14* G020 G035 G037 G039 G060 G420 H1 H103 H161 H4 H403 H441 H462
 H8 J0 J011 J3 J351 J5 J563 M210 M211 M240 M273 M281 M282
 M320 M414 M431 M510 M520 M531 M540 M782 M904 M905 M910 P210 P220
 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R01382-K; R01382-T; R01382-M; R14207-K; R14207-T; R14207-M
 M2 *15* D011 D019 D022 D621 D680 H4 H401 H481 H5 H541 H7 H715 H721
 H8 M1 M126 M132 M210 M211 M212 M240 M272 M281 M311 M321 M343
 M373 M391 M412 M431 M512 M520 M530 M540 M782 M904 M905 M910 P210
 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R01096-K; R01096-T; R01096-M; R10482-K; R10482-T; R10482-M
 M2 *16* D013 D015 D030 D160 F012 F013 F014 F015 F016 F123 H1 H100 H121
 H4 H405 H424 H5 H521 H8 J0 J011 J1 J111 J5 J521 L9
 L942 M1 M126 M141 M210 M211 M240 M283 M320 M412 M431 M511 M521
 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446
 P452 P631 P632 P633
 RIN: 45408
 DCN: R04792-K; R04792-T; R04792-M
 M2 *17* A351 A940 A960 C108 C550 C710 C720 C801 C802 C803 C804 C805 C807
 H4 H405 H484 H8 J0 J011 J1 J171 K0 L8 L814 L821 L832
 M280 M315 M321 M332 M344 M349 M381 M391 M411 M431 M510 M520 M530
 M540 M620 M630 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434
 P446 P452 P631 P632 P633
 DCN: R18589-K; R18589-T; R18589-M
 M2 *18* D011 D022 D029 E111 H1 H102 H103 H121 H181 H5 H541 H6 H602
 H641 H8 M210 M211 M212 M272 M273 M281 M282 M315 M321 M331 M342
 M383 M391 M412 M431 M511 M520 M530 M540 M782 M904 M905 M910 P210
 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R00287-K; R00287-T; R00287-M
 M2 *19* G020 G031 G035 G037 G038 G060 G420 H1 H103 H161 H4 H403 H441
 H462 H8 J0 J011 J3 J351 J5 J563 M210 M211 M240 M273 M281
 M282 M320 M414 M431 M510 M520 M531 M540 M782 M904 M905 M910 P210
 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R00210-K; R00210-T; R00210-M; R04583-K; R04583-T; R04583-M
 M2 *20* F011 F012 F015 F521 H1 H181 H2 H201 H3 H321 H4 H401 H481
 H8 M210 M211 M240 M281 M312 M321 M342 M383 M391 M413 M431 M510
 M521 M530 M540 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433
 P434 P446 P452 P631 P632 P633

DCN: R01257-K; R01257-T; R01257-M
M2 *21* G013 G019 G100 H5 H542 H8 K0 L3 L340 L399 M280 M315 M321
M332 M342 M383 M391 M414 M431 M510 M520 M532 M540 M782 M904 M905
P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
DCN: R09295-K; R09295-T; R09295-M; R14775-K; R14775-T; R14775-M
M2 *22* D011 D021 D029 D240 G017 G100 H4 H401 H461 H5 H543 H8 J5
J521 L9 L942 M1 M112 M210 M211 M272 M283 M320 M412 M431 M511
M520 M531 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434
P446 P452 P631 P632 P633
RIN: 02826
DCN: R04080-K; R04080-T; R04080-M
M2 *23* D013 D021 D030 D240 J5 J521 L9 L942 L980 M210 M211 M240 M283
M320 M412 M431 M511 M520 M530 M540 M782 M904 M905 P210 P220 P310
P330 P431 P433 P434 P446 P452 P631 P632 P633
RIN: 66132
DCN: R19215-K; R19215-T; R19215-M
M2 *24* G020 G021 G022 G341 H1 H103 H181 H4 H401 H481 H6 H602 H608
H642 H685 H8 M210 M214 M231 M273 M282 M311 M313 M321 M332 M343
M344 M373 M391 M414 M431 M510 M520 M531 M540 M782 M904 M905 P210
P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
DCN: R19175-K; R19175-T; R19175-M
M2 *25* F012 F014 F015 F016 F541 G013 G100 H1 H101 H122 H6 H602 H641
L9 L910 M1 M113 M210 M212 M240 M281 M320 M413 M431 M510 M521
M531 M540 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434
P446 P452 P631 P632 P633
DCN: R00153-K; R00153-T; R00153-M; R14989-K; R14989-T; R14989-M
M2 *26* D013 D021 D621 F012 F433 H4 H401 H481 H6 H685 H689 H8 M1
M126 M132 M280 M311 M323 M343 M344 M353 M373 M391 M392 M412 M431
M511 M521 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433
P434 P446 P452 P631 P632 P633
DCN: R11259-K; R11259-T; R11259-M; R14991-K; R14991-T; R14991-M
M2 *27* D023 D621 H1 H100 H102 H141 H181 H5 H541 H8 M210 M211 M272
M281 M315 M321 M331 M342 M383 M391 M412 M431 M511 M520 M530 M540
M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631
P632 P633
DCN: R14990-K; R14990-T; R14990-M; R14992-K; R14992-T; R14992-M
M2 *28* D013 D931 H1 H100 H121 J5 J592 J9 L9 L910 M280 M320 M412
M431 M511 M520 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431
P433 P434 P446 P452 P631 P632 P633
DCN: RA03YY-K; RA03YY-T; RA03YY-M
M2 *29* D011 D019 D970 F012 F013 F015 F113 H1 H121 H2 H201 H4 H403
H422 H481 H8 K0 L8 L813 L821 L834 M280 M311 M321 M342 M373
M391 M412 M431 M511 M521 M530 M540 M782 M904 M905 P210 P220 P310
P330 P431 P433 P434 P446 P452 P631 P632 P633
RIN: 44763 44763
DCN: R03766-K; R03766-T; R03766-M; R10155-K; R10155-T; R10155-M
M2 *30* F012 F014 F015 F542 H6 H601 H621 J5 J522 L9 L910 M280 M320
M413 M431 M510 M521 M530 M540 M782 M904 M905 M910 P210 P220 P310
P330 P431 P433 P434 P446 P452 P631 P632 P633
DCN: R00165-K; R00165-T; R00165-M; R14958-K; R14958-T; R14958-M
M2 *31* D011 D931 J5 J592 J9 L9 L943 M280 M320 M412 M431 M511 M520
M530 M540 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434
P446 P452 P631 P632 P633
DCN: R00020-K; R00020-T; R00020-M
M2 *32* D011 D931 F011 F014 F015 F521 H1 H181 H2 H201 H3 H321 H5
H592 H9 L9 L943 L999 M1 M126 M142 M210 M211 M273 M281 M320
M412 M431 M511 M521 M530 M540 M782 M904 M905 M910 P210 P220 P310
P330 P431 P433 P434 P446 P452 P631 P632 P633
DCN: R01259-K; R01259-T; R01259-M
M2 *33* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421

H481 H6 H604 H621 H8 J5 J522 K0 L8 L813 L821 L834 L9
 L910 M280 M311 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540
 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434 P446 P452
 P631 P632 P633
 DCN: R00084-K; R00084-T; R00084-M
 M2 *34* D013 D931 H1 H100 H121 J5 J592 J9 L9 L910 M280 M320 M412
 M431 M511 M520 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431
 P433 P434 P446 P452 P631 P632 P633
 DCN: R08236-K; R08236-T; R08236-M
 M2 *35* D011 D013 D931 F012 F013 F015 F113 H1 H100 H122 H2 H201 H4
 H402 H421 H481 H6 H602 H621 H8 L943 M280 M311 M321 M342 M373
 M391 M412 M431 M511 M521 M530 M540 M782 M904 M905 P210 P220 P310
 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: RA035K-K; RA035K-T; RA035K-M
 M2 *36* F011 F012 F013 F014 F015 F019 F113 F542 H1 H100 H121 H2 H211
 H4 H403 H422 H481 H8 J5 J521 K0 L8 L811 L821 L834 L9
 L910 M280 M311 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540
 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631
 P632 P633
 DCN: RA021Q-K; RA021Q-T; RA021Q-M
 M2 *37* D011 D013 D931 F012 F013 F014 F015 F113 H1 H100 H122 H2 H201
 H4 H403 H422 H481 H6 H601 H621 H8 L943 M280 M311 M321 M342
 M373 M391 M412 M431 M511 M521 M530 M540 M782 M904 M905 P210 P220
 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: RA0CGV-K; RA0CGV-T; RA0CGV-M
 M2 *38* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421
 H481 H6 H604 H682 H7 H721 H8 J5 J522 L9 L910 M280 M311
 M312 M321 M332 M342 M353 M373 M391 M413 M431 M510 M522 M530 M540
 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631
 P632 P633
 DCN: RA8S3P-K; RA8S3P-T; RA8S3P-M
 M2 *39* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H403 H422
 H481 H7 H715 H721 H8 J5 J522 L9 L910 M210 M212 M240 M281
 M311 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904
 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: RA8S3O-K; RA8S3O-T; RA8S3O-M
 M2 *40* D011 D931 J5 J592 J9 L9 L943 M280 M320 M412 M431 M511 M520
 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446
 P452 P631 P632 P633
 DCN: RA03YX-K; RA03YX-T; RA03YX-M
 M2 *41* F011 F012 F013 F014 F015 F019 F113 F580 H1 H100 H121 H2 H211
 H4 H403 H422 H481 H8 J5 J521 K0 L8 L812 L821 L834 L9
 L910 L999 M280 M311 M321 M342 M373 M391 M413 M431 M510 M522 M530
 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452
 P631 P632 P633
 RIN: 00212
 DCN: RA1SBO-K; RA1SBO-T; RA1SBO-M
 M2 *42* F012 F013 F014 F015 F019 F113 F710 H4 H403 H422 H481 H8 J0
 J011 J3 J311 M1 M116 M280 M311 M321 M342 M373 M391 M413 M431
 M510 M522 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433
 P434 P446 P452 P631 P632 P633
 DCN: R20492-K; R20492-T; R20492-M
 M2 *43* D011 D013 D840 F012 F013 F014 F015 F113 H1 H100 H122 H2 H201
 H4 H403 H422 H481 H8 J0 J011 J3 J311 L943 M280 M311 M321
 M342 M373 M391 M412 M431 M511 M521 M530 M540 M782 M904 M905 P210
 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 RIN: 01261
 DCN: RA8D9S-K; RA8D9S-T; RA8D9S-M
 M2 *44* D011 D019 D931 F012 F013 F014 F015 F113 H1 H100 H122 H2 H201
 H4 H403 H422 H481 H8 K0 L8 L811 L821 L834 L943 M280 M311

M321 M342 M373 M391 M412 M431 M511 M521 M530 M540 M782 M904 M905
 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R06741-K; R06741-T; R06741-M
 M2 *45* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421
 H481 H6 H601 H621 H8 J5 J522 K0 L8 L813 L821 L834 L9
 L910 M280 M311 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540
 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434 P446 P452
 P631 P632 P633
 DCN: R00037-K; R00037-T; R00037-M
 M2 *46* D011 D013 D931 H1 H100 H121 H181 H2 H201 H4 H401 H481 H8
 J5 J521 L9 L910 M280 M314 M321 M332 M342 M383 M391 M412 M431
 M511 M520 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433
 P434 P446 P452 P631 P632 P633
 DCN: RA8RQM-K; RA8RQM-T; RA8RQM-M
 M2 *47* D011 D013 D931 H1 H100 H121 H181 H2 H201 H4 H401 H481 H5
 H581 H8 J5 J521 K0 L6 L640 L9 L910 M280 M311 M312 M321
 M332 M342 M373 M383 M391 M412 M431 M511 M520 M530 M540 M782 M904
 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R04178-K; R04178-T; R04178-M; RA04GU-K; RA04GU-T; RA04GU-M
 M2 *48* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H403 H422
 H481 H8 J5 J522 K0 L8 L812 L821 L834 L9 L910 M280 M311
 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904 M905
 M910 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R00177-K; R00177-T; R00177-M
 M2 *49* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421
 H481 H8 J5 J522 K0 L8 L813 L821 L834 L9 L910 M210 M211
 M240 M281 M311 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540
 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434 P446 P452
 P631 P632 P633
 DCN: R00036-K; R00036-T; R00036-M
 M2 *50* F011 F012 F013 F014 F015 F019 F113 F432 H2 H211 H4 H403 H422
 H481 H8 J5 J522 K0 L8 L812 L821 L834 L9 L941 M280 M311
 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904 M905
 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R08223-K; R08223-T; R08223-M
 M2 *51* D012 D013 E530 H4 H402 H421 H481 H8 K0 L3 L355 L8 L811
 L821 L834 L9 L943 M280 M311 M321 M342 M373 M391 M412 M431 M511
 M520 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434
 P446 P452 P631 P632 P633
 RIN: 08295
 DCN: R17554-K; R17554-T; R17554-M
 M2 *52* D011 D013 E290 F012 F013 F014 F015 F113 H1 H100 H122 H2 H201
 H211 H4 H403 H422 H481 H8 L943 M210 M211 M273 M281 M311 M321
 M342 M373 M391 M412 M431 M511 M521 M530 M540 M782 M904 M905 P210
 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 RIN: 50796
 DCN: RA804T-K; RA804T-T; RA804T-M
 M2 *53* F011 F012 F013 F014 F015 F019 F113 F570 H2 H211 H4 H403 H422
 H481 H8 J0 J011 J3 J311 K0 L8 L812 L821 L834 M280 M311
 M321 M342 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904 M905
 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 RIN: 00096
 DCN: R04428-K; R04428-T; R04428-M
 M2 *54* D011 D013 D931 G036 G543 H1 H100 H121 H161 H2 H201 H4 H402
 H482 H8 J5 J521 L9 L910 M280 M311 M322 M342 M373 M392 M412
 M431 M511 M520 M530 M541 M782 M904 M905 P210 P220 P310 P330 P431
 P433 P434 P446 P452 P631 P632 P633
 DCN: RA0U3W-K; RA0U3W-T; RA0U3W-M
 M2 *55* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421
 H481 H6 H685 H8 J5 J522 L9 L910 M280 M311 M322 M342 M344

M353 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904 M905 P210
 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R06576-K; R06576-T; R06576-M; R23075-K; R23075-T; R23075-M
 M2 *56* D011 D013 D931 H1 H100 H121 H181 H2 H201 H4 H402 H482 H5
 H581 H8 J5 J521 K0 L6 L640 L9 L910 M280 M311 M313 M321
 M332 M342 M343 M383 M392 M412 M431 M511 M520 M530 M540 M782 M904
 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R06407-K; R06407-T; R06407-M
 M2 *57* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421
 H481 H8 J5 J522 L9 L910 M210 M212 M240 M281 M311 M321 M342
 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904 M905 P210 P220
 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R10039-K; R10039-T; R10039-M
 M2 *58* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421
 H481 H6 H603 H682 H7 H721 H8 J5 J522 K0 L8 L813 L821
 L834 L9 L910 M280 M311 M312 M321 M332 M342 M353 M373 M391 M413
 M431 M510 M522 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431
 P433 P434 P446 P452 P631 P632 P633
 DCN: R04821-K; R04821-T; R04821-M
 M2 *59* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H402 H421
 H481 H6 H602 H681 H8 J5 J522 L9 L910 M280 M311 M312 M321
 M332 M342 M353 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904
 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: RA8S3Q-K; RA8S3Q-T; RA8S3Q-M
 M2 *60* D011 D013 D931 H1 H100 H121 H181 H2 H201 H4 H402 H482 H8
 J5 J521 L9 L910 M280 M314 M321 M332 M343 M383 M391 M412 M431
 M511 M520 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433
 P434 P446 P452 P631 P632 P633
 DCN: R23076-K; R23076-T; R23076-M
 M2 *61* D011 D013 D931 H4 H402 H482 H8 J5 J522 L9 L910 M280 M315
 M321 M332 M343 M383 M391 M412 M431 M511 M520 M530 M540 M782 M904
 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R21048-K; R21048-T; R21048-M
 M2 *62* D011 D022 D621 H1 H102 H103 H121 H181 H6 H602 H641 M210 M212
 M273 M282 M315 M321 M331 M342 M383 M391 M412 M431 M511 M520 M530
 M540 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434 P446
 P452 P631 P632 P633
 DCN: R00078-K; R00078-T; R00078-M; R14988-K; R14988-T; R14988-M
 M2 *63* C316 G013 G019 G100 H1 H101 H142 K0 K4 K442 M1 M121 M142
 M280 M320 M414 M431 M510 M520 M532 M540 M782 M904 M905 M910 P210
 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: R00472-K; R00472-T; R00472-M
 M2 *64* F011 F012 F013 F014 F015 F019 F113 F542 H2 H211 H4 H403 H422
 H481 H8 J5 J522 L9 L910 M210 M211 M240 M281 M311 M321 M342
 M373 M391 M413 M431 M510 M522 M530 M540 M782 M904 M905 P210 P220
 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: RA5TW2-K; RA5TW2-T; RA5TW2-M
 M2 *65* D013 D931 F012 F013 F014 F015 F113 H1 H100 H122 H2 H201 H4
 H403 H422 H481 H8 M280 M311 M321 M342 M373 M391 M412 M431 M511
 M521 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434
 P446 P452 P631 P632 P633
 DCN: RA8S3M-K; RA8S3M-T; RA8S3M-M
 M2 *66* D011 D025 D030 E330 H1 H100 H141 H5 H521 H8 K0 L4 L463
 L9 L951 M210 M211 M240 M272 M281 M311 M321 M342 M373 M391 M412
 M431 M511 M520 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431
 P433 P434 P446 P452 P631 P632 P633
 RIN: 12848
 DCN: R03874-K; R03874-T; R03874-M
 M2 *67* D012 D014 D770 H1 H181 H2 H201 J0 J011 J1 J111 J5 J521
 M210 M211 M212 M240 M273 M281 M320 M412 M431 M511 M520 M530 M540

M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434 P446 P452
 P631 P632 P633
 RIN: 01683
 DCN: R01243-K; R01243-T; R01243-M
 M2 *68* D011 D019 D931 F012 F013 F014 F015 F113 G013 G100 H1 H100 H103
 H122 H181 H2 H201 H4 H402 H421 H481 H5 H541 H8 J0 J011
 J3 J321 K0 L8 L812 L821 L834 L943 M210 M211 M272 M273 M281
 M282 M311 M312 M321 M332 M342 M343 M349 M371 M373 M391 M412 M431
 M511 M521 M531 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433
 P434 P446 P452 P631 P632 P633
 DCN: R11093-K; R11093-T; R11093-M
 M2 *69* D011 D931 H1 H100 H121 L9 L943 M280 M320 M412 M431 M511 M520
 M530 M540 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434
 P446 P452 P631 P632 P633
 DCN: R00318-K; R00318-T; R00318-Q; R00318-M; R18196-K; R18196-T;
 R18196-Q; R18196-M
 M2 *70* D011 D931 J5 J521 L9 L941 M280 M320 M412 M431 M511 M520 M530
 M540 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433 P434 P446
 P452 P631 P632 P633
 DCN: R00285-K; R00285-T; R00285-Q; R00285-M
 M2 *71* D012 D013 D932 J5 J523 L9 L910 L921 M280 M320 M412 M431 M511
 M520 M530 M540 M782 M904 M905 M910 P210 P220 P310 P330 P431 P433
 P434 P446 P452 P631 P632 P633
 DCN: R00295-K; R00295-T; R00295-Q; R00295-M; R09540-K; R09540-T;
 R09540-Q; R09540-M
 M2 *72* F011 F012 F013 F014 F015 F017 F019 F113 F542 H1 H100 H121 H2
 H211 H4 H402 H421 H481 H6 H601 H608 H622 H8 J5 J521 K0
 L818 L834 L835 L9 L910 M280 M311 M321 M342 M373 M391 M413 M431
 M510 M522 M530 M540 M782 M904 M905 P210 P220 P310 P330 P431 P433
 P434 P446 P452 P631 P632 P633
 DCN: RA0EH0-K; RA0EH0-T; RA0EH0-Q; RA0EH0-M
 M2 *73* D011 D019 D931 F012 F013 F014 F015 F113 H1 H102 H122 H2 H201
 H4 H403 H422 H481 H6 H602 H683 H7 H721 H8 L943 M280 M311
 M314 M321 M331 M342 M362 M373 M391 M412 M431 M511 M521 M530 M540
 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631
 P632 P633
 DCN: RA8RV7-K; RA8RV7-T; RA8RV7-Q; RA8RV7-M
 M2 *74* D011 D019 D931 F012 F013 F014 F015 F113 H1 H102 H122 H2 H201
 H4 H404 H422 H482 H7 H721 H8 L943 M280 M311 M315 M321 M333
 M342 M373 M383 M391 M412 M431 M511 M521 M530 M540 M782 M904 M905
 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 DCN: RA68IY-K; RA68IY-T; RA68IY-Q; RA68IY-M
 M2 *75* B615 B701 B713 B720 B815 B831 D011 D019 D931 F012 F013 F014 F015
 F113 G060 G740 H1 H102 H122 H2 H201 H4 H402 H422 H8 L943
 M1 M126 M143 M280 M311 M321 M342 M373 M391 M411 M431 M511 M521
 M530 M541 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446
 P452 P631 P632 P633
 RIN: 03624
 DCN: RA8RV3-K; RA8RV3-T; RA8RV3-Q; RA8RV3-M
 M2 *76* D011 D019 D931 F012 F013 F014 F015 F113 G060 G740 H1 H102 H122
 H2 H201 H4 H403 H422 H481 H8 L943 M1 M126 M143 M280 M311
 M321 M342 M373 M391 M412 M431 M511 M521 M530 M541 M782 M904 M905
 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633
 RIN: 03624
 DCN: RA8RV0-K; RA8RV0-T; RA8RV0-Q; RA8RV0-M
 M2 *77* B615 B701 B713 B720 B815 B831 D011 D019 D931 F012 F013 F014 F015
 F019 F111 F113 H1 H102 H122 H2 H201 H4 H402 H422 H8 L943
 M280 M311 M322 M342 M373 M392 M411 M431 M511 M522 M530 M540 M782
 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632
 P633

DCN: RA8RUV-K; RA8RUV-T; RA8RUV-Q; RA8RUV-M

M2 *78* D011 D019 D931 F012 F013 F014 F015 F019 F111 F113 H1 H100 H122
H2 H201 H4 H402 H422 H5 H581 H8 L943 M280 M311 M322 M342
M373 M392 M412 M431 M511 M522 M530 M540 M782 M904 M905 P210 P220
P310 P330 P431 P433 P434 P446 P452 P631 P632 P633

DCN: RA8RUT-K; RA8RUT-T; RA8RUT-Q; RA8RUT-M

M2 *79* B615 B701 B713 B720 B815 B831 D011 D019 D931 F012 F013 F014 F015
F113 G010 G100 H1 H102 H122 H2 H201 H4 H402 H422 H8 L943
M280 M311 M322 M342 M373 M392 M411 M431 M511 M521 M531 M540 M782
M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452 P631 P632
P633

DCN: RA8RUP-K; RA8RUP-T; RA8RUP-Q; RA8RUP-M

M2 *80* D011 D019 D931 F012 F013 F014 F015 F113 G010 G100 H1 H100 H122
H2 H201 H4 H402 H422 H5 H581 H8 L943 M280 M311 M322 M342
M373 M392 M412 M431 M511 M521 M531 M540 M782 M904 M905 P210 P220
P310 P330 P431 P433 P434 P446 P452 P631 P632 P633

DCN: RA8RUM-K; RA8RUM-T; RA8RUM-Q; RA8RUM-M

M2 *81* B615 B701 B713 B720 B815 B831 D011 D019 D931 F012 F013 F014 F015
F113 H1 H102 H122 H2 H201 H4 H402 H422 H8 L943 M210 M215
M232 M273 M281 M311 M321 M342 M373 M391 M411 M431 M511 M521 M530
M540 M782 M904 M905 P210 P220 P310 P330 P431 P433 P434 P446 P452
P631 P632 P633

DCN: RA8RXC-K; RA8RXC-T; RA8RXC-Q; RA8RXC-M

M2 *82* D011 D019 D931 F012 F013 F014 F015 F113 H1 H102 H122 H2 H201
H4 H403 H422 H481 H8 L943 M210 M215 M232 M273 M281 M311 M321
M342 M373 M391 M412 M431 M511 M521 M530 M540 M782 M904 M905 P210
P220 P310 P330 P431 P433 P434 P446 P452 P631 P632 P633

DCN: RA8RX5-K; RA8RX5-T; RA8RX5-Q; RA8RX5-M

M2 *87* H1 H103 H181 H7 H721 J0 J011 J1 J171 M210 M211 M273 M282
M315 M321 M331 M342 M381 M391 M416 M431 M782 M904 M905

DCN: RA7Q0X-K; RA7Q0X-Q; RA7Q0X-M

M2 *88* H7 H721 J0 J011 J2 J271 M210 M211 M213 M232 M262 M272 M281
M320 M416 M431 M782 M904 M905 M910

DCN: R00479-K; R00479-Q; R00479-M

=> d ibib abs hitstr l61 1-24

L61 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:151888 HCAPLUS

DOCUMENT NUMBER: 137:226208

TITLE: Inhibitory effects of flavonoids on human immunodeficiency virus type-1 integrase

AUTHOR(S): Tewtrakul, Supinya; Miyashiro, Hirotosugu; Hatrori, Masao; Yoshinaga, Tomokazu; Fujiwara, Tamio; Tomimori, Tsuyoshi; Kizu, Haruhisa; Miyaichi, Yukinori

CORPORATE SOURCE: Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Toyama, 930-0194, Japan

SOURCE: Wakan Iyakugaku Zasshi (2001), 18(6), 229-238

CODEN: WIZAEI; ISSN: 1340-6302

PUBLISHER: Wakan Iyaku Gakkai

DOCUMENT TYPE: Journal

LANGUAGE: English


AB One hundred and eighty-three flavonoids were screened for their inhibitory effects on HIV-1 integrase (IN) using a multiplate integration assay (MIA). Of the tested flavonoids, 6-hydroxyluteolin, scutellarein, pedalitin, scutellarin, baicalein dimer, hypolaetin, 7-O-benzyl-6-hydroxyluteolin and baicalein showed appreciable inhibition with IC₅₀ values of 0.4, 0.6, 1.3, 1.7, 2.0, 2.1, 3.0 and 3.6 μ M, resp. The potent inhibition was observed with flavonoids having at least one pair of vicinal hydroxyl groups and the activity was highly dependent on the number of vicinal hydroxyl groups. On the other hand, the inhibitory activity tended to be decreased by replacing a hydroxyl group with one of methoxyl, acetoxyl, isopropoxyl, isopentenyl, benzyloxyl, glucuronyl and glycosyl groups. No flavanones, flavanonols and chalcones examined in this experiment showed any significant inhibitory activity.

IT 973-67-1 34334-69-5, Cirsiliol

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitory effects of flavonoids on human immunodeficiency virus type-1 integrase)

RN 973-67-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:50468 HCAPLUS

DOCUMENT NUMBER: 134:110442

TITLE: Use of flavones, coumarins and related compounds to treat infections

INVENTOR(S): Prendergast, Patrick T.

PATENT ASSIGNEE(S): Ire.

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001003681	A2	20010118	WO 2000-IB1039	20000707 <--
WO 2001003681	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2375647	AA	20010118	CA 2000-2375647	20000707 <--
EP 1223928	A2	20020724	EP 2000-948187	20000707 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003504327	T2	20030204	JP 2001-508962	20000707 <--
US 6555523	B1	20030429	US 2000-612025	20000707 <--
PRIORITY APPLN. INFO.: US 1999-142894P P 19990708 <--				
US 1999-163089P P 19991102 <--				
WO 2000-IB1039 W 20000707 <--				

OTHER SOURCE(S): MARPAT 134:110442

AB The invention provides the use of flavin compds. such as cirsiolol, 3',4'-diacetoxy-5,6,7-trimethoxyflavone, or naringin in the treatment of infections, particularly for viral (e.g., HCV, HIV, a picornavirus genus virus or a respiratory virus) or parasite (e.g., toxoplasmosis) infections. Also provided are compns. for use in the methods.

IT 973-67-1, Baicalein trimethyl ether 34334-69-5,


Cirsiolol 34334-69-5D, Cirsiolol, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(flavones, coumarins, and related compds. to treat infections)

RN 973-67-1 HCAPLUS


CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 34334-69-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-
(9CI) (CA INDEX NAME)

RN 34334-69-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-
(9CI) (CA INDEX NAME)

L61 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:603194 HCAPLUS

DOCUMENT NUMBER: 129:211696

TITLE: Antimicrobial product comprising an antibiotic
and a potentiating flavonoidINVENTOR(S): Richards, Robert Michael Edward; Durham, David Garnet;
Liu, Iain Xiaojun

PATENT ASSIGNEE(S): British Technology Group Ltd., UK

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9836750	A1	19980827	WO 1998-GB512	19980218 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,				

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

CA 2281524	AA	19980827	CA 1998-2281524	19980218 <--
AU 9861081	A1	19980909	AU 1998-61081	19980218 <--
AU 726471	B2	20001109		
ZA 9801337	A	19990818	ZA 1998-1337	19980218 <--
EP 973523	A1	20000126	EP 1998-905514	19980218 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
BR 9807444	A	20000425	BR 1998-7444	19980218 <--
JP 2001512473	T2	20010821	JP 1998-536379	19980218 <--
MX 9907686	A	20000228	MX 1999-7686	19990819 <--
PRIORITY APPLN. INFO.:			GB 1997-3532	A 19970220 <--
			GB 1997-26401	A 19971212 <--
			WO 1998-GB512	W 19980218 <--

OTHER SOURCE(S): MARPAT 129:211696

GI




I

AB An antimicrobial product is disclosed which comprises, for simultaneous, sep. or sequential administration, a flavonoid I (R3, R5, R6, R7, R8, Ra, Rb, Rc, Rd, Re = H, OZ; Z = H, lower alkyl, glycosyl, leaving group; X, Y = H, or X and Y together is a double bond), or a **pharmaceutically** acceptable salt thereof; and an **antibiotic**. The flavonoid may be present in such an amount so as to potentiate the action of the **antibiotic**. When the **antibiotic** is a β -lactam **antibiotic**, the resulting medicament may be used for treating or preventing bacterial infections which are at least partially resistant to treatment by the β -lactam **antibiotic** alone.

IT 973-67-1, 5,6,7-Trimethoxyflavone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antibiotic** and a potentiating flavonoid for antimicrobial product)

RN 973-67-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:451935 HCAPLUS

DOCUMENT NUMBER: 127:171111

TITLE: **Antiviral** activity of 5,6,7-trimethoxyflavone and its potentiation of the antiherpes activity of acyclovir

AUTHOR(S): Hayashi, Kyoko; Hayashi, Toshimitsu; Otsuka, Hidaeki; Takeda, Yoshio

CORPORATE SOURCE: Department of Virology, Toyama Medical and Pharmaceutical University, Toyama, 930-01, Japan

SOURCE: Journal of Antimicrobial Chemotherapy (1997), 39(6), 821-824

CODEN: JACHDX; ISSN: 0305-7453

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A naturally occurring flavone, 5,6,7-trimethoxyflavone (TMF), isolated from the plant *Callicarpa japonica*, was subjected to **antiviral** assays. The compound exhibited relatively high inhibitory effects on herpes simplex virus type 1 (HSV-1), human cytomegalovirus and poliovirus. The anti-HSV-1 action was not due to the inhibition of virus adsorption, entry and viral protein synthesis, but might involve, at least in part, a virucidal activity, which results in a suppression of viral binding to host cells at an early replication stage. TMF and acyclovir were synergistic in their anti-HSV activities at levels below the 50% inhibitory concns. for **antiviral** activity.


IT 973-67-1, 5,6,7-Trimethoxyflavone

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**antiviral** activity of 5,6,7-trimethoxyflavone and potentiation of antiherpes activity of acyclovir)

RN 973-67-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L61 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:120329 HCAPLUS

DOCUMENT NUMBER: 124:289188

TITLE: Synthesis, antimicrobial and **antiviral** activities of novel polyphenolic compounds

AUTHOR(S): Parmar, V. S.; Bisht, K. S.; Jain, Rajni; Singh, Suddham; Sharma, S. K.; Gupta, Suman; Malhotra, Sanjay; Tyagi, O. D.; Vardhan, Anand; et al.

CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110 007, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1996)

), 35B(3), 220-32

CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER:

Publications & Information Directorate, CSIR

DOCUMENT TYPE:

Journal

LANGUAGE:

English


AB Natural and synthetic phenolic compds. belonging to the classes of flavones, coumarins, xanthenes, chalcones, isoflavones and desoxybenzoins have been prepared or isolated from plant species, characterized and tested against a battery of 10 pathogenic bacteria, 1 yeast, 3 fungi and 3 viruses. Only two of the compds. show some moderate bacteriostatic activity against gram-pos. cocci, but are like all other products inactive against gram-neg. bacteria, yeasts and fungi. On the contrary, two flavones, one desoxybenzoin and one diacetoxycoumarin exhibited pronounced antiviral properties against some of the viruses tested. Five other coumarin analogs possessed moderate anti-poliomyelitis properties and one xanthone is to a lesser extent active against Vesicular stomatitis virus. Of the compds. synthesized nine are new compds.

IT 973-67-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis, antimicrobial and antiviral activities of novel polyphenolic compds.)

RN 973-67-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L61 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:1006222 HCAPLUS

DOCUMENT NUMBER: 124:134764

TITLE: Cytocidal and antimicrobial activities of flavonoids

AUTHOR(S): Funayama, Shinji; Komiyama, Kanki; Miyaichi, Yukinori; Tomimori, Tsuyoshi; Nozoe, Shigeo

CORPORATE SOURCE: Fac. Pharmaceutical Sciences, Tohoku Univ., Sendai, 980, Japan

SOURCE: Natural Medicines (1995), 49(3), 322-8

CODEN: NMEDEO; ISSN: 1340-3443

PUBLISHER:

Japanese Society of Pharmacognosy

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB One hundred and eighty-two flavonoids were studied for their cytocidal activities on B16 melanoma cells in vitro and antimicrobial activities on Bacillus-subtilis, Staphylococcus aureus, Escherichia coli, Saccharomyces sake, Micrococcus luteus, Staphylococcus aureus, Candida albicans and Piricularia oryzae. Twelve flavonoids showed moderate cytocidal activities and 25 flavonoids antimicrobial activities. Most of the flavanones having no sugar moiety showed antimicrobial activities whereas none of the flavonols and flavonolignans tested showed inhibitory activities on these microorganisms.


IT 973-67-1 34334-69-5 172918-51-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(cytotoxic and antimicrobial activities of flavonoids)


RN 973-67-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)




RN 34334-69-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 172918-51-3 HCAPLUS

CN 4H-1-Benzopyran-4-one, 3-iodo-5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L61 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:963493 HCAPLUS

DOCUMENT NUMBER: 124:8616

TITLE: Preparation of pyrone derivatives as protease inhibitors and antiviral agents

INVENTOR(S): Domagala, John Michael; Lunney, Elizabeth; Para, Kimberly Suzanne; Prasad, Josyula Venkata Nagendr; Tait, Bradley Dean

PATENT ASSIGNEE(S): Parke, Davis and Co., USA

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9514013	A1	19950526	WO 1994-US12257	19941026 <--
W: AM, AU, BG, BY, CA, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV,				

MD, NO, NZ, PL, RO, RU, SI, SK, TJ, UA, UZ
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 US 6005103 A 19991221 US 1994-319769 19941012 <--
 AU 9480911 A1 19950606 AU 1994-80911 19941026 <--
 AU 687465 B2 19980226
 EP 729465 A1 19960904 EP 1994-932042 19941026 <--
 EP 729465 B1 20030122
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
 JP 09505293 T2 19970527 JP 1994-514457 19941026 <--
 RU 2136674 C1 19990910 RU 1996-113097 19941026 <--
 AT 231502 E 20030215 AT 1994-932042 19941026 <--
 FI 9602020 A 19960531 FI 1996-2020 19960513 <--
 NO 9602016 A 19960515 NO 1996-2016 19960515 <--
 NO 315747 B1 20031020
 PRIORITY APPLN. INFO.:
 US 1993-155028 A 19931119 <--
 US 1994-319769 A 19941012 <--
 WO 1994-US12257 W 19941026 <--
 OTHER SOURCE(S): MARPAT 124:8616
 GI




AB Title compds. [I; A,A1 = bond, phenylene, cycloalkylene, etc.; R3 = H, (CH2)pR4, etc.; R4 = H, (cyclo)alkyl, Ph, etc.; R5 = H, (cyclo)alkyl, Ph, etc.; X = OR1, NHR1, CH2OR1, CO2R4; R1 = R4 or COR4; W, W1, W3 = bond, O, CO, CH:CH, etc.; W2 = CR3, CO, CO2, CH:CH, etc. when n = 0; W2 = bond, O, NR3, etc. when n > 0; m,n = 0-4; p = 0-2; Z,Y = O or S] were prepared
 Thus, 2-(Me2HC)C6H4(CO2Et)2 was cyclocondensed with 4-(pyridin-3-ylmethoxy)acetophenone to give title compound II which had IC50 of 0.65μM against HIV-1 activity in H9 cells in vitro.
 IT 13909-73-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrone derivs. as protease inhibitors and **antiviral**
agents)

RN 13909-73-4 HCAPLUS

CN Ethanone, 1-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



L61 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:951171 HCAPLUS

DOCUMENT NUMBER: 123:339737

TITLE: Preparation of pyrone derivatives as protease
inhibitors and **antiviral** agents

INVENTOR(S): Domagala, John Michael; Ellsworth, Edmund Lee; Lunney,
Elizabeth; Ortwine, Daniel Fred; Para, Kimberly
Suzanne; Prasad, Josyula Venkata Nagendr; Sawyer,
Tomi; Tait, Bradley Dean

PATENT ASSIGNEE(S): Parke, Davis and Co., USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9514014	A2	19950526	WO 1994-US12367	19941026 <--
WO 9514014	A3	19950615		
W: AM, AU, BG, BY, CA, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, NO, NZ, PL, RO, RU, SI, SK, TJ, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5808062	A	19980915	US 1994-319768	19941012 <--
AU 9481276	A1	19950606	AU 1994-81276	19941026 <--
AU 682417	B2	19971002		
EP 729466	A1	19960904	EP 1995-900457	19941026 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09505295	T2	19970527	JP 1994-514461	19941026 <--
RU 2153497	C2	20000727	RU 1996-113056	19941026 <--
FI 9602019	A	19960520	FI 1996-2019	19960513 <--
NO 9602015	A	19960515	NO 1996-2015	19960515 <--
PRIORITY APPLN. INFO.:			US 1993-155028	A 19931119 <--
			US 1994-319768	A 19941012 <--
			WO 1994-US12367	W 19941026 <--
OTHER SOURCE(S):			MARPAT 123:339737	
GI				




AB Title compds. [I; R = OR₁, NHR₁, CH₂OR₁, SR₁, CO₂R₄; R₁ = R₄ or COR₄; R₄ = H, (cyclo)alkyl, Ph, heteroaryl; R₅ = H, (cyclo)alkyl, Ph, etc.; R₆ = A(CH₂)_nW(CH₂)_mW₁R₃; R₃ = H, (CH₂)_pR₄, etc.; R₇ = W₂A₁(CH₂)_mW₃R₃; A, A₁ = bond, phenylene, heterocyclylene, etc.; W, W₁, W₃ = bond, O, NR₃, CO, etc.; W₂ = O, S, NR₃, O₂C, etc.; Y, Z = O or S; m, n = 0-4; p = 0-2] were prepared. Thus, 4-(R₃H₂CO)C₆H₄COMe (R₃ = 3-pyridyl) was converted to the O-trimethylsilyl enol ether which was cyclocondensed with 2-(Me₃HC)C₆H₄S(CO₂Et)₂ to give title compound II. The latter had EC₅₀ of 0.65 μM for protection of H9 cells against HIV-1 infection in vitro.

IT 13909-73-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrone derivs. as protease inhibitors and **antiviral** agents)

RN 13909-73-4 HCAPLUS

CN Ethanone, 1-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



L61 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:298442 HCAPLUS

DOCUMENT NUMBER: 120:298442

TITLE: Antitumor Agents. 150. 2',3',4',5',5,6,7-Substituted 2-Phenyl-4-quinolones and Related Compounds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization

AUTHOR(S): Li, Leping; Wang, Hui-Kang; Kuo, Sheng-Chu; Wu, Tian-Shung; Lednicer, Dan; Lin, Chii M.; Hamel, Ernest; Lee, Kuo-Hsiung

CORPORATE SOURCE: School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA


SOURCE: Journal of Medicinal Chemistry (1994), 37(8), 1126-35

CODEN: JMCMAR; ISSN: 0022-2623


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II

AB As part of the continuing search for potential anticancer drug candidates in the 2-phenyl-4-quinolone series, a series of 6,7-methylenedioxy-substituted and unsubstituted 2-phenyl-4-quinolones, as well as related compds. were prepared. Their in vitro inhibition of human tumor cell lines and tubulin polymerization is reported. In general, a good correlation was found between cytotoxicity and inhibition of tubulin polymerization. Quinolones I [R = R2 = H, R3R4 = OCH2O, R1 = H, OMe, NMe2; R =

H,

R1, R2 = OMe, R3R4 = OCH2O; R = F, Cl, R1, R2 = H, R3R4 = OCH2O; R = R2 = R4 = H, R1 = NMe2, OMe, R3 = OMe] showed potent inhibitory effects in both assays. All rigid analogs II [n = 2, 3, R5 = H; n = 2, R5 = OMe] and trimethoxy-substituted compds. showed little or no activity. Substitution at the 4'-position also resulted in compds. with little or no activity, except for hydroxyl or Me groups at this position. Further investigation is underway to determine if substitution at the 3'-position will result in compds. with increased activity.


IT 13909-73-4, 2,3,4-Trimethoxyacetophenone

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of neoplasm-inhibiting phenylquinolones)

RN 13909-73-4 HCAPLUS

CN Ethanone, 1-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



L61 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:524131 HCAPLUS

DOCUMENT NUMBER: 117:124131

TITLE: Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids

AUTHOR(S): Blomgren, Henric; Kling-Andersson, Gunilla

CORPORATE SOURCE: Radiumhemmet, Karolinska Hosp., Stockholm, 104 01, Swed.

SOURCE: Anticancer Research (1992), 12(3), 981-6 ✓

CODEN: ANTRD4; ISSN: 0250-7005

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In an attempt to find new methods for the treatment of malignant gliomas, a number of tests have been performed to learn whether growth of such cells in vitro may be affected by agents which interfere with the biosynthesis of eicosanoids. It was observed that DNA-synthesis of short-term monolayer cultures could be blocked by compds. which inhibit cyclooxygenase and/or lipoyxygenase dependent arachidonic acid metabolism. The strongest inhibitory activities were noted in serum-free culture medium using compds. interfering with the activity of lipoyxygenases. One explanation of these results could be that the growth of human malignant gliomas is dependent on certain eicosanoids which may be synthesized by the malignant cells themselves.


IT 34334-69-5, Cirsiliol

RL: BIOL (Biological study)

(as eicosanoid formation inhibitor, glioma of humans growth inhibition by)

RN 34334-69-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-(9CI) (CA INDEX NAME)



L61 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:466636 HCAPLUS

DOCUMENT NUMBER: 117:66636

TITLE: Antimicrobial constituents of *Gomphrena martiana* and *Gomphrena boliviana*

AUTHOR(S): Pomilio, Alicia B.; Buschi, Carlos A.; Tomes, Claudia N.; Viale, Alberto A.

CORPORATE SOURCE: Fac. Cienc. Exactas Nat., Univ. Buenos Aires, Buenos Aires, 1428, Argent.

SOURCE: Journal of Ethnopharmacology (1992), 36(2), 155-61

CODEN: JOETD7; ISSN: 0378-8741

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The antimicrobial activity of exts. and constituents of *G. martiana* and *G. boliviana* (Amaranthaceae) were determined to identify the compds. responsible for the folk-medicinal use of these plants. Each extract was evaluated against 20 microorganisms, including gram-pos. and gram-neg. bacteria, spore-forming gram-pos. bacteria, an acid-fast bacterium, a fungus and two yeasts. Fractionation of each petroleum ether (PE) extract yielded five 5,6,7-trisubstituted flavones that were sep. tested showing high activity against *Mycobacterium phlei* (min. inhibitory concentration (MIC) 15, 20 and 75 µg/mL) approaching that of com. bactericides. Other natural and synthetic flavonoids with diverse structures were also tested to define structure-activity relationships. Each EtOH extract was subsequently fractionated and monitored by bioassays leading to isorhamnetin 3-O-β-robinobioside (MIC 50 µg/mL) in both instances. This glycoside is reported here for the first time in *G. boliviana*.


IT 75413-07-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(from Gomphrena species, antimicrobial activity of)

RN 75413-07-9 HCAPLUS

CN 4H-1-Benzopyran-4-one, 3,5,6,7-tetramethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L61 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:187627 HCAPLUS

DOCUMENT NUMBER: 116:187627

TITLE: Ru 41.740 triggers human mononuclear blood cells to release tumor growth inhibitory factors in vitro

AUTHOR(S): Blomgren, Henric

CORPORATE SOURCE: Karolinska Hosp., Stockholm, S-104 01, Swed.

SOURCE: International Journal of Immunopharmacology (1992), 14(2), 185-90

CODEN: IJIMDS; ISSN: 0192-0561

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Ru 41.740 (Biostim) is an immunostimulating **drug** of microbial origin which may stimulate human mononuclear blood cells (mainly monocytes) to release soluble factors which inhibit replication of several tumor cell lines in vitro. Since this effect may be of clin. importance in the treatment of cancer, tests have been conducted to find methods to augment this secretion. In vitro tests suggested that this non-specific antitumor activity of Biostim may not be enhanced by concomitant treatment of patients with inhibitors of cyclooxygenase and lipoxigenases or by interferons α , β , γ or the hemopoietic growth factors GM-CSF and G-CSF.


IT 34334-69-5, Cirsiliol

RL: BIOL (Biological study)

(Ru 41.740 antitumor activity response to, in human monocytes)

RN 34334-69-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (9CI) (CA INDEX NAME)



L61 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1990:423280 HCAPLUS

DOCUMENT NUMBER: 113:23280


TITLE: Chalcones: a new class of antimitotic agents

AUTHOR(S): Edwards, Michael L.; Stemerick, David M.; Sunkara, Prasad S.

CORPORATE SOURCE: Merrell Dow Res. Inst., Cincinnati, OH, 45215, USA
SOURCE: Journal of Medicinal Chemistry (1990),
33(7), 1948-54
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:23280
AB A series of chalcones was evaluated as antimitotic agents. One of these,
(E)-2,5-(MeO)₂C₆H₃COCMe:CHC₆H₄NMe₂ (I), was an effective antimitotic agent
at 4 nM in an in vitro HeLa cell test system. When evaluated in exptl.
tumor models in vivo, I exhibited antitumor activity against L1210
leukemia and B16 melanoma.
IT 13909-73-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation reaction of, with (diethylamino)- or
acetamidobenzaldehyde)
RN 13909-73-4 HCAPLUS
CN Ethanone, 1-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




L61 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1989:449912 HCAPLUS
DOCUMENT NUMBER: 111:49912
TITLE: Effect of chemical constituents from plants on
12-O-tetradecanoylphorbol-13-acetate-induced
inflammation in mice
AUTHOR(S): Yasukawa, Ken; Takido, Michio; Takeuchi, Mieko;
Nakagawa, Shigeki
CORPORATE SOURCE: Coll. Sci. Technol.; Nihon Univ., Tokyo, 101, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1989),
37(4), 1071-3
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The induction of edema in the mouse ear is a reliable in vivo assay for
tumor promoters. Therefore, inhibitors of 12-O-tetradecanoylphorbol-13-
acetate (TPA)-induced ear edema are most likely to be inhibitors of skin
tumor promotion. Besides the application for this assay for the screening
of compds., it also allows comparison of the activities of groups of
related compds. such as flavonoids. Results obtained in this way showed
that the double bond at C-2 and C-3 of the flavonoid structure is a
prerequisite for antitumor-promoting activity, and indicated that activity
in this screening assay for inhibitors of TPA-induced ear edema reflects
the antitumor-promoting effect in 2-stage carcinogenesis.
IT 973-67-1
RL: BIOL (Biological study)
(anti-tumor-promoting activity of, in TPA-induced inflammation model,
structure in relation to)
RN 973-67-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L61 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1989:417724 HCAPLUS
 DOCUMENT NUMBER: 111:17724
 TITLE: Chalcone derivatives useful in treating gout and their preparation
 INVENTOR(S): Edwards, Michael L.; Stemerick, David M.; Sunkara, Sai P.
 PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals, Inc., USA
 SOURCE: Eur. Pat. Appl., 16 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 287901	A1	19881026	EP 1988-105541	19880407 <--
EP 287901	B1	19900801		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8814165	A1	19881013	AU 1988-14165	19880405 <--
AU 608821	B2	19910418		
ZA 8802388	A	19881130	ZA 1988-2388	19880405 <--
AT 55108	E	19900815	AT 1988-105541	19880407 <--
US 4863968	A	19890905	US 1988-285331	19881214 <--
PRIORITY APPLN. INFO.:			US 1987-36214	A 19870409 <--
			EP 1988-105541	A 19880407 <--
OTHER SOURCE(S):	MARPAT 111:17724			
GI				



AB Chalcone derivs. I [Ar = 2,5-dimethoxyphenyl, 2,3,4-trimethoxyphenyl, or 3,4,5-trimethoxyphenyl; R1 = H, Br, Cl, or C1-4 alkyl; R2 = NR2 or NHC(O)R (R = C1-4 alkyl)] and their pharmaceutically acceptable salts are described. I represents a new class of antimitotic agents and is applicable to treatment of gout. Preparation of I is detailed. 2,5-Dimethoxypropiophenone (0.09 mol), piperidine (1.8 mL), 4-dimethylaminobenzaldehyde (0.009 mol), EtOH (15 mL), and HOAc (0.9 mL) were refluxed through mol. sieves until the reaction was complete as indicated by TLC (25% EtOAc/hexane). Solvent was removed and α -methyl-4-dimethylamino-2',5'-dimethoxychalcone (II) was purified by silica el chromatog. and recrystn. HeLa cells were incubated for 1 h in the presence of II, then for an addnl. 18 h in medium free of II. Min.

effective concentration for mitotic arrest in the incubation assay was 0.06 µg/mL. A parenteral formulation contained II 1.0, polyoxyethylene sorbitan monooleate 2.0, and NaCl 0.128 g, and H₂O q.s. ad 20.0 mL.


IT 13909-73-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with dimethylaminobenzaldehyde in gout inhibitor preparation)

RN 13909-73-4 HCAPLUS

CN Ethanone, 1-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



L61 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:417706 HCAPLUS

DOCUMENT NUMBER: 111:17706

TITLE: Chalcone derivatives useful in controlling growth of tumor tissue and their preparation

INVENTOR(S): Edwards, Michael L.; Stemerick, David M.; Sunkara, Sai P.

PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals, Inc., USA

SOURCE: Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 288794	A2	19881102	EP 1988-105540	19880407 <--
EP 288794	A3	19881123		
EP 288794	B1	19940608		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4904697	A	19900227	US 1987-36227	19870409 <--
AU 8814164	A1	19881013	AU 1988-14164	19880405 <--
AU 599220	B2	19900712		
ZA 8802391	A	19881130	ZA 1988-2391	19880405 <--
AT 106723	E	19940615	AT 1988-105540	19880407 <--
PRIORITY APPLN. INFO.:			US 1987-36227	A 19870409 <--
			EP 1988-105540	A 19880407 <--

OTHER SOURCE(S): MARPAT 111:17706

GI



AB Chalcone derivs. I [Ar = 2,5-dimethoxyphenyl, 2,3,4-trimethoxyphenyl, or 3,4,5-trimethoxyphenyl; R₁ = H, Br, Cl, or C₁-4 alkyl; R₂ = NR₂ or NHC(O)R


(R = C1-4 alkyl)] and their pharmaceutically acceptable salts are described. I represents a new class of anti-mitotic agents useful in controlling growth of tumor tissue. Preparation of I is detailed. 2,5-Dimethoxypropiophenone (0.009 mol), piperidine (1.8 mL), 4-dimethylaminobenzaldehyde (0.009 mol), EtOH (15 mL), and HOAc (0.9 mL) were refluxed through mol. sieves until the reaction was complete as indicated by TLC (25% EtOAc/hexane). Solvent was removed and α -methyl-4-dimethylamino-2',5'-dimethoxychalcone (II) was purified by silica gel chromatog. and recrystn. Mice were inoculated i.p. with 1 + 105 L1210 leukemia cells on day zero of a standard animal survival protocol. II (6.25-50.0 mg/kg in 5% PVP) increased survival time by a factor of 1.26-1.54 over survival time for control animals. A parenteral formulation contained II 1.0, polyoxyethylene sorbitan monooleate 2.0, and NaCl 0.128 g, and H₂O q.s. ad 20.0 mL.

IT 13909-73-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dimethylaminobenzaldehyde in neoplasm inhibitor preparation)

RN 13909-73-4 HCAPLUS

CN Ethanone, 1-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



L61 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:604515 HCAPLUS

DOCUMENT NUMBER: 109:204515

TITLE: Effect of flavonoids on tumor promoter's activity

AUTHOR(S): Yasukawa, K.; Takido, M.; Takeuchi, M.; Nitta, K.

CORPORATE SOURCE: Coll. Sci. Technol., Nihon Univ., Tokyo, 101, Japan

SOURCE: Progress in Clinical and Biological Research (1988), 280 (Plant Flavonoids Biol. Med. 2:

Biochem., Cell., Med. Prop.), 247-50

CODEN: PCBRD2; ISSN: 0361-7742

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The inflammation induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) in mouse ears was inhibited by some of the flavonoids tested. Also, the 2-step carcinogenesis by 7,12-dimethylbenz[a]anthracene and TPA in mice was inhibited by 4 flavonoids. The effect of the flavonoids on the cell-mediated immunosuppression in the 2-step carcinogenesis was also tested; none of the agents affected this process after 7 wk, but the immunosuppression observed by carcinogenesis after 14 wk was antagonized by mauritianin.

IT 973-67-1

RL: BIOL (Biological study)
(inflammation induction by tumor promoter TPA response to)

RN 973-67-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L61 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:95685 HCAPLUS

DOCUMENT NUMBER: 106:95685

TITLE: Arachidonate 5-lipoxygenase inhibitors show potent antiproliferative effects on human leukemia cell lines
 AUTHOR(S): Tsukada, Tetsuya; Nakashima, Kunio; Shirakawa, Shigeru
 CORPORATE SOURCE: Sch. Med., Mie Univ., Tsu, 514, Japan
 SOURCE: Biochemical and Biophysical Research Communications (1986), 140(3), 832-6
 CODEN: BBRC9; ISSN: 0006-291X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cirsiol [34334-69-5] and AA861 [80809-81-0], specific arachidonate 5-lipoxygenase [80619-02-9] inhibitors, showed potent antiproliferative effects on human leukemic cell lines K562, Molt4B and HL60. On the other hand, HeLa cells were not affected by these **drugs**. In the inhibitor-treated and growth-retarded leukemia cells, the rates of synthesis of DNA, RNA and protein were markedly decreased. These results suggested that arachidonate 5-lipoxygenase or leukotrienes would play essential roles in cellular functions of leukemic cells.


IT 34334-69-5, Cirsiol

RL: PRP (Properties)

(antiproliferative effects of, on leukemia cells of human)

RN 34334-69-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-(9CI) (CA INDEX NAME)



L61 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:421715 HCAPLUS

DOCUMENT NUMBER: 105:21715

TITLE: Iridoids and flavonoids of Teucrium polium herb

AUTHOR(S): Rizk, A. M.; Hammouda, F. M.; Rimpler, H.; Kamel, A.

CORPORATE SOURCE: Sci. Appl. Res. Cent., Qatar Univ., Doha, Qatar

SOURCE: Planta Medica (1986), (2), 87-8


CODEN: PLMEAA; ISSN: 0032-0943

DOCUMENT TYPE: Journal


LANGUAGE: English

AB The iridoid glycoside teucardoside (I) and the flavonoids salvigenin and cirsiol were isolated from T. polium var. pilosum and T. polium var.

alba. I showed neg. cancerostatic activity in P 388 leukemia system.
IT 34334-69-5
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
BIOL (Biological study); OCCU (Occurrence)
(of *Teucrium polium*)
RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-
(9CI) (CA INDEX NAME)



L61 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1986:61607 HCAPLUS
DOCUMENT NUMBER: 104:61607
TITLE: Lipoxxygenase inhibition and tumor promotor inhibition
by medicinal plant components
AUTHOR(S): Kato, Ryuichi; Nakadate, Akio; Yamamoto, Satoshi
CORPORATE SOURCE: Med. Sch., Keio Univ., Tokyo, Japan
SOURCE: Wakan Iyaku Gakkaishi (1985), 2(1), 162-3
CODEN: WIGAES; ISSN: 0289-730X
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB Several oriental drug components, including flavonoids,
chalcones, caffeic acid derivs., and related compds. were tested for their
effects on mouse epidermal lipoxxygenase (LO) [9029-60-1] activity and on
the induction of epidermal ornithine decarboxylase (ODC) [9024-60-6] by
the tumor promotor 12-o-tetradecanoylphorbol-13-acetate (TPA)
[16561-29-8] and on TPA promotion of DMBA-initiated skin tumor. Topical
application of quercetin [117-39-5], morin [480-16-0], fisetin
[528-48-3], kaempferol [520-18-3], baicalein [491-67-8], cirsiolol [34334-69-5], 3,4,2',4'-tetrahydroxychalcone [21849-70-7],
3,4,2'-trihydroxychalcone [6272-43-1], and 3,4,4'-trihydroxychalcone
[92496-89-4] markedly inhibited epidermal LO and TPA-induced epidermal ODC
activities and promotion of DMBA tumorigenesis by TPA.
3,4-Dihydroxychalcone [72704-76-8] and esculetin [305-01-1] also had
similar, but to a lesser degree, inhibitory effects. In contrast, no such
inhibitory effects on the epidermal LO activity, TPA-induced epidermal ODC
activity, and TPA promotion of skin tumor were observed after topical
application of (+)-catechin [154-23-4], (-)-epicatechin [490-46-0],
chalcone [94-41-7], caffeic acid [331-39-5], ferulic acid [1135-24-6],
and chlorogenic acid [327-97-9].
IT 34334-69-5
RL: BIOL (Biological study)
(lipoxxygenase and tumor promotion inhibition by)
RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-
(9CI) (CA INDEX NAME)



L61 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:14552 HCAPLUS

DOCUMENT NUMBER: 104:14552

TITLE: **Antiviral** activity of natural occurring flavonoids in vitro

AUTHOR(S): Tsuchiya, Yoshinori; Shimizu, Mineo; Hiyama, Yoshiyuki; Itoh, Kiyoshi; Hashimoto, Yoshinobu; Nakayama, Mitsuru; Horie, Tokunaru; Morita, Naokata
 CORPORATE SOURCE: Kyoto Res. Inst., Kaken Pharm. Co., Ltd., Kyoto, 607, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1985), 33(9), 3881-6

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The **antiviral** activity of a wide range of naturally occurring flavonoids was investigated in vitro. Chrysosplenol B [603-56-5] and chrysosplenol C [23370-16-3], which are contained specifically in Chrysosplenium plants, and axillarin [5188-73-8] showed potent **antiviral** activity, especially rhinovirus. A comparison of the activities of the compds. tested indicated that 3-methoxyl and 5-hydroxyl groups in the flavone skeleton were both necessary for **antiviral** activity against rhinovirus, and the activity may also be affected by various groups at other positions. The other flavonoids tested had little or no **antiviral** activity against herpes simplex virus, influenza virus and rhinovirus. Apparently, Chrysosplenium plants, which contain large amts. of chrysosplenol B and chrysosplenol C, may be useful as medicinal herbs against the common cold caused by rhinovirus infection.


IT 973-67-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**antiviral** activity of)

RN 973-67-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (9CI) (CA INDEX NAME)




L61 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1978:526100 HCAPLUS


DOCUMENT NUMBER: 89:126100

TITLE: New furanoid ent-clerodanes from Baccharis tricuneata

AUTHOR(S): Wagner, Hildebert; Seitz, Renate; Lotter, Hermann; Herz, Werner
 CORPORATE SOURCE: Inst. Pharm. Arzneimittellehre, Univ. Muenchen, Munich, Fed. Rep. Ger.
 SOURCE: Journal of Organic Chemistry (1978), 43(17), 3339-45
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I




II

AB Because of the antitumor and **antiviral** properties of a crude extract, the constituents of the Columbian medicinal plant *Baccharis tricuneata* var *tricuneata* were investigated. The hexane extract yielded 4 new ent-clerodanes, bacchotricuneatins A-D, whose structures were elucidated, primarily by ¹H and ¹³C NMR spectrometry. Proof for the structure and stereochem. of A (I) and B (II) was obtained by x-ray anal. Isolated from the ether extract were cirsimaritin, cirsiolol, and scopoletin.

IT 34334-69-5
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
 (of *Baccharis tricuneata*)

RN 34334-69-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-(9CI) (CA INDEX NAME)



L61 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1973:11468 HCAPLUS

DOCUMENT NUMBER: 78:11468

TITLE: Synthesis and **antiviral** activity of 4'-hydroxy-5,6,7,8-tetramethoxyflavone

AUTHOR(S): Burnham, Weldon S.; Sidwell, Robert W.; Tolman, Richard L.; Stout, Mason G.

CORPORATE SOURCE: ICN Nucleic Acid Res. Inst., Irvine, CA, USA

SOURCE: Journal of Medicinal Chemistry (1972),

15(10), 1075-6

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE:

Journal

LANGUAGE:

English


AB 4'-Hydroxy-5,6,7,8-tetramethoxyflavone (I) [36950-98-8] showed pronounced activity in cell culture (nasopharynx carcinoma cells) against rhinovirus type 13, some activity against type 56, but little activity against type 1A. I inhibited the type 13 virus-induced cytopathogenic effect and decreased the quantity of infectious virus recoverable from cells by up to 105-fold. To synthesize I, tangeretin (4',5,6,7,8-pentamethoxyflavone) was degraded in refluxing KOH-EtOH to 2'-hydroxy-3',4',5',6'-tetramethoxyacetophenone, which was converted with p-benzyloxybenzaldehyde in KOH-EtOH to 4-benzyloxy-2'-hydroxy-3',4',5',6'-tetramethoxychalcone; cyclization with SeO₂ and removal of the benzyl group by hydrogenation yielded I.

IT 3162-28-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 3162-28-5 HCAPLUS

CN Ethanone, 1-(2-hydroxy-3,4,5,6-tetramethoxyphenyl)- (9CI) (CA INDEX NAME)



L61 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:488224 HCAPLUS

DOCUMENT NUMBER: 77:88224

TITLE: Synthesis of eupatoretin and eupatin

AUTHOR(S): Ch'en, Fa-Ch'ing

CORPORATE SOURCE: Dep. Chem., Natl. Taiwan Univ., Taipei, Taiwan

SOURCE: Taiwan Kexue (1971), 25(3-4), 106

CODEN: TKHSAU; ISSN: 0015-7791

DOCUMENT TYPE:

Journal

LANGUAGE:

Chinese

GI For diagram(s), see printed CA Issue.

AB The title compds. (I, R = Me and H, resp.), the anticancer constituents of Eupatorium semiserratum, were prepared

IT 22248-14-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 22248-14-2 HCAPLUS

CN Ethanone, 1-(6-hydroxy-2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

